<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Skell-E HTML Preview</title>
  <link rel="stylesheet" href="../assets/style.css">
</head>
<body>
  <article>
    <header>
        <h1 id="title">Pfizer is 'deeply sorry'</h1>
        <a href="#" class="button copy-link" onclick="copyToClipboard(); return false;">Copy Code</a>
    </header>
    <main id="code-to-copy" class="container">
<p>I recently came across a report about Pfizer being accused of bringing discredit to the pharmaceutical industry after a complaint was made regarding their promotion of the COVID-19 vaccine on social media. The complaint alleged that senior Pfizer executives used Twitter to promote an unlicensed COVID vaccine. Let's take a closer look at the details of this case.</p>

<h2>Prescription Medicines Code of Practice Authority (PMCPA) Ruling</h2>

<p>The Prescription Medicines Code of Practice Authority (PMCPA) panel ruled that Pfizer breached five clauses of the 2019 code:</p>

<ul>

<li><strong>Clause 2:</strong> Bringing discredit upon and reducing confidence in the pharmaceutical industry</li>

<li><strong>Clause 3.1:</strong> Promoting an unlicensed medicine</li>

<li><strong>Clause 7.2:</strong> Making misleading claims, not reflecting available evidence on adverse reactions </li>

<li><strong>Clause 9.1:</strong> Failing to maintain high standards</li>

</ul>

<h2>Details of the Complaint</h2>

<p>The complaint related to a message posted on Twitter back in November 2020 by senior Pfizer employees. The post contained limited information regarding the efficacy of the vaccine candidate, with no safety information provided. On the balance of probability, the Pfizer UK employees' Twitter connections would include both UK members of the public as well as UK health professionals.</p>

<h2>Panel's Findings and Ruling</h2>

<p>The panel noted that the tweet clearly referred to the outcomes of the Pfizer and BioNTech vaccine being developed to protect against COVID-19. They highlighted that Clause 3.1 prohibits the promotion of a medicine prior to the grant of a marketing authorization. </p>

<p>The panel was concerned that important safety information relating to the vaccine candidate, such as potential adverse reactions, was not provided. They ruled this a breach of Clause 7.2, stating material must be sufficiently complete to enable the recipient to form their own opinion of the medicine's therapeutic value.</p>

<p>It was also noted that the senior employee who retweeted the post had completed a social media training module in October 2019. However, the activity, which was clearly outside company policy, was not taken down or deleted for a period of time.</p>

<h2>Pfizer's Response</h2>

<p>Pfizer's UK spokesman said the company fully recognized and accepted the issues highlighted by the PMCPA ruling. They were deeply sorry and stated it was accidental and unintentional. However, this marks the sixth time Pfizer has been reprimanded by the regulators over its promotion of the COVID vaccines.</p>

<h2>Commentary on Pharmaceutical Industry Regulation</h2>

<p>Ben Kingsley from a campaigning organization commented, "It's astonishing how many times Pfizer's senior executives have been found guilty of serious regulatory offenses, yet the consequences for Pfizer and the individuals concerned continue to be derisory. This hopeless system of regulation for a multi-billion, life-and-death industry has become a sham in dire need of reform."</p>

<p>This case highlights the importance of responsible and transparent communication from pharmaceutical companies, especially when it comes to unlicensed medicines and vaccines. It also raises questions about the effectiveness of current regulations and the need for potential reform in holding companies accountable for breaches and misleading promotions.</p>
    </main>
  </article>
  <footer><span class="skell-e-sig">&Sigma;&lt;3||-E</p></footer>
  <script src="../assets/script.js"></script>
</body>
</html>